Cargando…

First-line treatment of ovarian cancer: questions and controversies to address

Detalles Bibliográficos
Autor principal:	Ledermann, Jonathan A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898654/ https://www.ncbi.nlm.nih.gov/pubmed/29662548 http://dx.doi.org/10.1177/1758835918768232

Ejemplares similares

First-line chemotherapy for ovarian cancer – the controversy continues
por: Kaye, S B
Publicado: (2002)

Questions & Controversies
por: Silke, J
Publicado: (2015)

Update on first-line treatment of advanced ovarian carcinoma
por: Kemp, Z, et al.
Publicado: (2013)

Open questions in autoimmunity: discussions from the 2013 Controversies in Rheumatology and Autoimmunity Meeting
por: Selmi, Carlo, et al.
Publicado: (2014)

Exertional sickling: questions and controversy
por: Blinder, Morey A., et al.
Publicado: (2014)

Screening for prostate cancer: Controversy? What controversy?
por: Ablin, R.J., et al.
Publicado: (2009)

Progression after discontinuation of bevacizumab in the first-line treatment of ovarian cancer
por: Nakai, Hidekatsu, et al.
Publicado: (2023)

Current questions and possible controversies in autophagy
por: Lindqvist, L M, et al.
Publicado: (2015)

Dopamine and serotonin in fear extinction: some key questions to be addressed
por: Vicario, Carmelo M, et al.
Publicado: (2020)

To PARPI or Not to PARPI BRCA Mutated Ovarian Cancer Following First-line Chemotherapy, That is the Question?
por: Rose, Peter G, et al.
Publicado: (2021)

Metformin in obesity, cancer and aging: addressing controversies
por: Berstein, Lev M.
Publicado: (2012)

Suboxone: History, controversy, and open questions
por: Sivils, Andy, et al.
Publicado: (2022)

Controversies
Publicado: (1896)

Controversy
Publicado: (1856)

Frontline Maintenance Treatment for Ovarian Cancer
por: Elyashiv, Osnat, et al.
Publicado: (2021)

Controversies in NSCLC: which second-line strategy after chemo-immunotherapy?
por: Moliner, L., et al.
Publicado: (2023)

Controversies in the Management of Endometrial Cancer
por: Hernandez, Enrique, et al.
Publicado: (2010)

Publishing controversy
por: Poole, Norman A.
Publicado: (2021)

Emerging therapies for hemophilia: controversies and unanswered questions
por: Arruda, Valder R., et al.
Publicado: (2018)

Questions and controversies: the role of necroptosis in liver disease
por: Dara, Lily, et al.
Publicado: (2016)

Polyp Resection - Controversial Practices and Unanswered Questions
por: von Renteln, Daniel, et al.
Publicado: (2017)

Introduction to the Molecules Special Edition Entitled ‘Heparan Sulfate and Heparin: Challenges and Controversies’: Some Outstanding Questions in Heparan Sulfate and Heparin Research
por: Yates, Edwin A, et al.
Publicado: (2019)

PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions
por: Ledermann, Jonathan A, et al.
Publicado: (2015)

Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
por: Ledermann, Jonathan A., et al.
Publicado: (2019)

Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer
por: Flynn, Michael J., et al.
Publicado: (2022)

Controversies in psychiatry
por: Thibaut, Florence
Publicado: (2018)

Controversies in EUS
por: Dietrich, Christoph F.
Publicado: (2021)

Remarkable Controversy
Publicado: (1860)

Medical Controversy
Publicado: (1857)

Treatment of pediatric chronic inflammatory demyelinating polyneuropathy: Challenges, controversies and questions
por: Desai, Jay, et al.
Publicado: (2015)

Controversies in colorectal cancer: First line treatment with epidermal growth factor inhibitors and RAS in 2014
por: Junior, Gilberto de Lima Lopes
Publicado: (2014)

Endocrine and metabolic late effects following cancer treatment: challenges and controversies
por: Gebauer, Judith, et al.
Publicado: (2022)

Flibanserin: Approval of a controversial drug for a controversial disorder
por: Sathyanarayana Rao, T. S., et al.
Publicado: (2015)

Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease
por: Bangham, Madeleine, et al.
Publicado: (2016)

Addressing Challenges and Controversies in the Management of Prostate Cancer with Multidisciplinary Teams
por: Shore, Neal D., et al.
Publicado: (2022)

Aquaporin water channels: unanswered questions and unresolved controversies
por: Agre, Peter, et al.
Publicado: (1995)

Questions and controversies surrounding the perception and neural coding of pitch
por: Oxenham, Andrew J.
Publicado: (2023)

Controversies around Xylitol
por: Söderling, Eva
Publicado: (2009)

Circumcision: Controversies and Prospects
por: Lukong, C. S.
Publicado: (2011)

Controversies in acetaminophen nephrotoxicity
por: Park, Woo Yeong
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2887g0ehcd9ckqmp9c0m6s9le2